Scaling-up treatment of depression and anxiety: a global return on investment analysis
Dan P. Chisholm
1
,
Kim Sweeny
2
,
Peter Peter M. Sheehan
2
,
Bruce A. Rasmussen
2
,
Filip Smit
3, 4
,
Pim Cuijpers
5
,
Shekhar Saxena
1
1
Department of Mental Health and Substance Abuse, WHO, Geneva, Switzerland
|
2
Victoria Institute of Strategic Economic Studies, Melbourne, VIC, Australia
|
4
Trimbos Institute (Netherlands Institute of Mental Health and Addiction), Utrecht, Netherlands
|
Publication type: Journal Article
Publication date: 2016-05-01
scimago Q1
wos Q1
SJR: 7.458
CiteScore: 44.3
Impact factor: 24.8
ISSN: 22150366, 22150374
PubMed ID:
27083119
Psychiatry and Mental health
Biological Psychiatry
Abstract
Depression and anxiety disorders are highly prevalent and disabling disorders, which result not only in an enormous amount of human misery and lost health, but also lost economic output. Here we propose a global investment case for a scaled-up response to the public health and economic burden of depression and anxiety disorders.In this global return on investment analysis, we used the mental health module of the OneHealth tool to calculate treatment costs and health outcomes in 36 countries between 2016 and 2030. We assumed a linear increase in treatment coverage. We factored in a modest improvement of 5% in both the ability to work and productivity at work as a result of treatment, subsequently mapped to the prevailing rates of labour participation and gross domestic product (GDP) per worker in each country.The net present value of investment needed over the period 2016-30 to substantially scale up effective treatment coverage for depression and anxiety disorders is estimated to be US$147 billion. The expected returns to this investment are also substantial. In terms of health impact, scaled-up treatment leads to 43 million extra years of healthy life over the scale-up period. Placing an economic value on these healthy life-years produces a net present value of $310 billion. As well as these intrinsic benefits associated with improved health, scaled-up treatment of common mental disorders also leads to large economic productivity gains (a net present value of $230 billion for scaled-up depression treatment and $169 billion for anxiety disorders). Across country income groups, resulting benefit to cost ratios amount to 2·3-3·0 to 1 when economic benefits only are considered, and 3·3-5·7 to 1 when the value of health returns is also included.Return on investment analysis of the kind reported here can contribute strongly to a balanced investment case for enhanced action to address the large and growing burden of common mental disorders worldwide.Grand Challenges Canada.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
5
10
15
20
25
30
35
40
45
|
|
|
Journal of Affective Disorders
41 publications, 4.03%
|
|
|
PLoS ONE
20 publications, 1.96%
|
|
|
Frontiers in Psychiatry
20 publications, 1.96%
|
|
|
The Lancet Psychiatry
18 publications, 1.77%
|
|
|
International Journal of Environmental Research and Public Health
17 publications, 1.67%
|
|
|
BMJ Open
15 publications, 1.47%
|
|
|
Frontiers in Psychology
13 publications, 1.28%
|
|
|
Frontiers in Public Health
13 publications, 1.28%
|
|
|
BMC Psychiatry
13 publications, 1.28%
|
|
|
Journal of Medical Internet Research
12 publications, 1.18%
|
|
|
Epidemiology and Psychiatric Sciences
11 publications, 1.08%
|
|
|
Psychological Medicine
10 publications, 0.98%
|
|
|
Cambridge Prisms Global Mental Health
10 publications, 0.98%
|
|
|
JMIR Mental Health
8 publications, 0.79%
|
|
|
JMIR Formative Research
8 publications, 0.79%
|
|
|
International Journal of Mental Health Systems
8 publications, 0.79%
|
|
|
BMC Public Health
8 publications, 0.79%
|
|
|
Depression and Anxiety
8 publications, 0.79%
|
|
|
BJPsych Open
7 publications, 0.69%
|
|
|
Journal of Psychiatric Research
7 publications, 0.69%
|
|
|
World Psychiatry
7 publications, 0.69%
|
|
|
Molecular Psychiatry
6 publications, 0.59%
|
|
|
BMC Health Services Research
6 publications, 0.59%
|
|
|
The Lancet
6 publications, 0.59%
|
|
|
Social Science and Medicine
6 publications, 0.59%
|
|
|
International Journal of Social Psychiatry
5 publications, 0.49%
|
|
|
Australian and New Zealand Journal of Psychiatry
5 publications, 0.49%
|
|
|
Nutrients
5 publications, 0.49%
|
|
|
Healthcare
5 publications, 0.49%
|
|
|
5
10
15
20
25
30
35
40
45
|
Publishers
|
50
100
150
200
250
|
|
|
Elsevier
219 publications, 21.51%
|
|
|
Springer Nature
164 publications, 16.11%
|
|
|
Wiley
68 publications, 6.68%
|
|
|
Frontiers Media S.A.
66 publications, 6.48%
|
|
|
JMIR Publications
58 publications, 5.7%
|
|
|
Taylor & Francis
48 publications, 4.72%
|
|
|
MDPI
47 publications, 4.62%
|
|
|
Cambridge University Press
41 publications, 4.03%
|
|
|
SAGE
41 publications, 4.03%
|
|
|
BMJ
31 publications, 3.05%
|
|
|
Public Library of Science (PLoS)
26 publications, 2.55%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
16 publications, 1.57%
|
|
|
Cold Spring Harbor Laboratory
15 publications, 1.47%
|
|
|
Mary Ann Liebert
7 publications, 0.69%
|
|
|
Oxford University Press
7 publications, 0.69%
|
|
|
Hindawi Limited
6 publications, 0.59%
|
|
|
Institute of Electrical and Electronics Engineers (IEEE)
6 publications, 0.59%
|
|
|
Royal College of Psychiatrists
5 publications, 0.49%
|
|
|
Annual Reviews
5 publications, 0.49%
|
|
|
Walter de Gruyter
5 publications, 0.49%
|
|
|
American Medical Association (AMA)
5 publications, 0.49%
|
|
|
Research Square Platform LLC
5 publications, 0.49%
|
|
|
SciELO
4 publications, 0.39%
|
|
|
American Psychiatric Association Publishing
3 publications, 0.29%
|
|
|
American College of Physicians
3 publications, 0.29%
|
|
|
IGI Global
3 publications, 0.29%
|
|
|
IOS Press
3 publications, 0.29%
|
|
|
Association for Computing Machinery (ACM)
3 publications, 0.29%
|
|
|
Emerald
3 publications, 0.29%
|
|
|
50
100
150
200
250
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
1k
Total citations:
1018
Citations from 2024:
228
(22.4%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Chisholm D. P. et al. Scaling-up treatment of depression and anxiety: a global return on investment analysis // The Lancet Psychiatry. 2016. Vol. 3. No. 5. pp. 415-424.
GOST all authors (up to 50)
Copy
Chisholm D. P., Sweeny K., Peter M. Sheehan P., Rasmussen B. A., Smit F., Cuijpers P., Saxena S. Scaling-up treatment of depression and anxiety: a global return on investment analysis // The Lancet Psychiatry. 2016. Vol. 3. No. 5. pp. 415-424.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/s2215-0366(16)30024-4
UR - https://doi.org/10.1016/s2215-0366(16)30024-4
TI - Scaling-up treatment of depression and anxiety: a global return on investment analysis
T2 - The Lancet Psychiatry
AU - Chisholm, Dan P.
AU - Sweeny, Kim
AU - Peter M. Sheehan, Peter
AU - Rasmussen, Bruce A.
AU - Smit, Filip
AU - Cuijpers, Pim
AU - Saxena, Shekhar
PY - 2016
DA - 2016/05/01
PB - Elsevier
SP - 415-424
IS - 5
VL - 3
PMID - 27083119
SN - 2215-0366
SN - 2215-0374
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2016_Chisholm,
author = {Dan P. Chisholm and Kim Sweeny and Peter Peter M. Sheehan and Bruce A. Rasmussen and Filip Smit and Pim Cuijpers and Shekhar Saxena},
title = {Scaling-up treatment of depression and anxiety: a global return on investment analysis},
journal = {The Lancet Psychiatry},
year = {2016},
volume = {3},
publisher = {Elsevier},
month = {may},
url = {https://doi.org/10.1016/s2215-0366(16)30024-4},
number = {5},
pages = {415--424},
doi = {10.1016/s2215-0366(16)30024-4}
}
Cite this
MLA
Copy
Chisholm, Dan P., et al. “Scaling-up treatment of depression and anxiety: a global return on investment analysis.” The Lancet Psychiatry, vol. 3, no. 5, May. 2016, pp. 415-424. https://doi.org/10.1016/s2215-0366(16)30024-4.